These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18511825)

  • 1. Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents.
    Skovronsky D
    J Nucl Med; 2008 Jun; 49(6):47N-48N. PubMed ID: 18511825
    [No Abstract]   [Full Text] [Related]  

  • 2. The exploratory IND.
    Mills G
    J Nucl Med; 2008 Jun; 49(6):45N-47N. PubMed ID: 18511824
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanics of the Food and Drug Administration's Form 1571: investigational new drug application.
    Novack G
    Retina; 2005 Dec; 25(8 Suppl):S96-S97. PubMed ID: 16374362
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 5. Good clinical practice in clinical drug trials--what you need to know.
    Soyebi K; Abosede ; Coker HA; Osuntoki ; Oyibos W; Keri H; Ogunsola S
    Nig Q J Hosp Med; 2008; 18(2):104-12. PubMed ID: 19068563
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase 0 trials: a platform for drug development?
    Lancet; 2009 Jul; 374(9685):176. PubMed ID: 19616703
    [No Abstract]   [Full Text] [Related]  

  • 7. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration.
    Feinsod M; Chambers WA
    Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good clinical practice--a practical experience.
    Ogunsola FT
    Nig Q J Hosp Med; 2008; 18(2):123-4. PubMed ID: 19068567
    [No Abstract]   [Full Text] [Related]  

  • 9. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fast track: federal agencies and the political demand for AIDS drugs.
    Foreman CH
    Brookings Rev; 1991; 9(2):30-7. PubMed ID: 10110828
    [No Abstract]   [Full Text] [Related]  

  • 12. Pediatric drug trials facing some obstacles.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(23):1720-1. PubMed ID: 16333025
    [No Abstract]   [Full Text] [Related]  

  • 13. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 14. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Mar; 75(44):10487-8. PubMed ID: 20383918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576
    [No Abstract]   [Full Text] [Related]  

  • 19. New FDA breakthrough-drug category--implications for patients.
    McClellan M; Sigal E
    N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577
    [No Abstract]   [Full Text] [Related]  

  • 20. New FDA breakthrough-drug category--implications for patients.
    Murray BE
    N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.